NovoLog® significantly reduces postprandial glucose (PPG) levels

NovoLog® demonstrated PPG control when used in a pump1

The graph below shows plasma glucose profiles in patients with type 1 diabetes who were assigned to NovoLog® or insulin lispro in pump use. (Another arm of the study used buffered human insulin, which is no longer available in the United States. Those results are not shown here.) After 16 weeks, NovoLog®provided better mean glucose levels after dinner than insulin lispro.

This study also examined rates of hypoglycemia vs insulin glulisine

In a 6-month study of patients with type 1 diabetes who added mealtime injections of either NovoLog® or regular human insulin to a basal regimen with NPH human insulin, NovoLog® provided significantly lower PPG levels than regular human insulin — a difference of 30 mg/dL.

A 6-month, randomized, open-label, parallel-group study enrolling 882 patients who had type 1 diabetes for at least 18 months. Patients taking NPH insulin were randomized to either NovoLog® or regular human insulin as part of basal-bolus therapy. There was a 6-month optional extension of this trial.3

Adapted from Raskin et al, 2002.3

Get insights from experts

Jaime Davidson, MD, FACP, MACE talks about the importance of PPG levels as a guide in treatment.

Related Information

How It Works

Review Clinical Studies

Selected Important Safety Information

Contraindications

NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients.

Warnings and Precautions

Never Share a NovoLog® FlexPen, NovoLog® FlexTouch®, PenFill® Cartridge, or PenFill® Cartridge Device Between Patients, even if the needle is changed. Patients using NovoLog® vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens.

Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased.

NovoLog® (insulin aspart injection) 100 U/mL Indications and Usage

NovoLog® (insulin aspart injection) 100 U/mL is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus.

Important Safety Information

Contraindications

NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients.

Warnings and Precautions

Never Share a NovoLog® FlexPen, NovoLog® FlexTouch®, PenFill® Cartridge, or PenFill® Cartridge Device Between Patients, even if the needle is changed. Patients using NovoLog® vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens.

Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased.

Hypoglycemia is the most common adverse effect of insulin therapy. The timing of hypoglycemia may reflect the time-action profile of the insulin formulation. Glucose monitoring is recommended for all patients with diabetes and is particularly important for patients using external pump infusion therapy.

To avoid medication errors and accidental mix-ups between NovoLog® and other insulin products, instruct patients to always check the insulin label before injection.

Severe, life-threatening, generalized allergy, including anaphylaxis, may occur with insulin products, including NovoLog®.

As with all insulins, NovoLog® use can lead to life-threatening hypokalemia, which then may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia and treat if indicated.

Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including NovoLog®. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered.

Malfunction of the insulin pump or insulin infusion set or insulin degradation can rapidly lead to hyperglycemia and ketoacidosis. Patients using insulin infusion pump therapy must be trained to administer insulin by injection and have alternate insulin therapy available in case of pump failure.

NovoLog®continuous subcutaneous infusion route (insulin pump): Do not mix NovoLog® with any other insulin or diluent.